Surgery Partners, a major operator of surgical facilities, has secured a sweeter takeover deal after a surprise rival bid failed to convince its board. HealthSpan Partners, an affiliate of the nonprofit health system Bon Secours Mercy Health, raised its cash offer to $25 a share from the $23.50 agreed in October. The move came after Surgery Partners said a $28-a-share proposal from an unnamed third party was not superior.
Why the board rejected the higher offer
At first glance, $28 looks better than $25. But Surgery Partners explained that the rival bid was non-binding and carried a longer path to closing, more regulatory uncertainty, and weaker contractual protections. In other words, the higher price came with more risk that the deal might never happen—or take much longer to complete.
For a company like Surgery Partners, which operates ambulatory surgery centers and surgical hospitals across the U.S., a smooth and certain exit is often more valuable than a slightly higher price that could fall apart. The board's decision highlights how merger negotiations weigh not just the headline number but the likelihood of actually getting paid.
The ticking fee: a price on delay
To make the revised offer more attractive, HealthSpan added a so-called ticking fee. If the deal closes after March 1 but before the October 23 outside date, shareholders will receive an extra amount of up to $1.61 per share. That means the maximum payout could reach $26.61 per share.
A ticking fee is essentially built-in interest for shareholders. If regulatory approvals take longer than expected, investors get compensated for the wait instead of bearing all the calendar risk themselves. This is a common feature in take-private deals, where the buyer wants to keep shareholders on board while the paperwork grinds through.
For merger-arbitrage traders—investors who buy shares of a target company hoping to profit from the deal closing—the ticking fee narrows the gap between the current stock price and the eventual payout. That can reduce the discount they demand, pulling the stock closer to the deal value.
Bain Capital's role
Bain Capital affiliates, which own about 39% of Surgery Partners, will not take the cash. Instead, they will roll their stake into equity in the combined company. This keeps them invested in the future of the business while reducing the amount of cash HealthSpan needs to pay upfront.
Rolling equity is a common arrangement in take-privates, especially when the buyer wants to preserve some continuity in ownership. It also signals that Bain believes in the long-term value of the company, even if it means giving up an immediate cash payout.
What it means for investors
For everyday investors, the key takeaway is that the stock is now trading close to the revised deal value. After the announcement, Surgery Partners shares closed around $25.98, which is within the range of $25 to $26.61 that the amended deal implies.
From here, day-to-day moves in the stock are likely to reflect the perceived odds of a timely close and regulatory sign-off, rather than the company's quarterly results. If the deal closes as expected in the first quarter of 2027, shareholders will receive the cash or, in Bain's case, equity in the new entity.
For those holding the stock, the ticking fee provides some protection against delays, but it doesn't eliminate the risk that the deal could fall through entirely. Regulatory approvals, antitrust reviews, and other conditions can still derail a transaction, even one that looks secure.
For merger-arbitrage traders, the revised terms make the deal more attractive because the ticking fee reduces the downside of a prolonged closing process. But the gap between the current price and the maximum payout also reflects the market's assessment of the deal's certainty.
The broader picture
Surgery Partners' situation is a reminder that in the world of mergers and acquisitions, the highest bid isn't always the best one. Boards must weigh price, certainty, and timing, and sometimes a lower but more reliable offer wins out.
For investors, the lesson is to look beyond the headline number and consider the terms, the timeline, and the likelihood of completion. In this case, the board's decision to stick with HealthSpan—and the added ticking fee—suggests they value a sure thing over a speculative one.
As the deal moves toward closing, investors will be watching for regulatory updates and any signs of delay. Until then, the stock's movements will be a barometer of confidence in the deal's success.
